Oragenics regains NYSE compliance, raises $16.5M, partners with Receptor.AI, advances Phase IIa trial

ORAGENICS INC

Regained NYSE American compliance on Oct 20, 2025, resolving equity deficiency and removing below-compliance indicator.
Completed $16.5M gross capital raise via Series H Convertible Preferred Stock in July 2025; net proceeds ~$15.2M.
Eliminated $3M note payable and restored stockholder equity above the $6M NYSE threshold.
Formed strategic collaboration with Receptor.AI to use AI-driven discovery for pipeline beyond concussion.
Anticipates Phase IIa trial initiation for ONP-002 in Q4 2025/Q1 2026 in Australia, with U.S. Phase IIb planning underway.

item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001493152-25-021749
form_type: 8-K
ticker: OGEN
cik: 0001174940
company_name: ORAGENICS INC
filed_at: 2025-11-12T23:59:59+00:00
discovered_at: 2026-05-14T18:02:38.933021+00:00
generated_at: 2026-05-16T20:54:34.761791+00:00
sec_items: ["8.01", "9.01"]
event_type: other_material
sentiment: positive
materiality_score: 0.75
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001493152-25-021749
json_url: https://secwatch.observer/filing/0001493152-25-021749.json
markdown_url: https://secwatch.observer/filing/0001493152-25-021749.md
text_url: https://secwatch.observer/filing/0001493152-25-021749.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1174940/000149315225021749/0001493152-25-021749-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1174940/000149315225021749/form8-k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001493152-25-021749

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.